Gland Pharma slips after ₹2,121 Cr block deal; Fosun Pharma likely seller
What's the deal? Gland Pharma shares fell on Friday after 75 lakh shares — a 4.5% stake — changed hands in a ₹2,121 Cr block deal. The transaction implied an average price of about ₹2,828 per share. Chinese promoter Fosun Pharma is likely the seller, though the buyer and seller were not officially confirmed.
Why now? Reports on Thursday indicated Fosun Pharma was looking to trim its stake in the drugmaker. The proposed sale of up to 5% was initially pegged at ₹2,279.5 Cr, with a floor price of ₹2,763 per share — a 5% discount to Thursday's close — and a 12-month lock-up on further sales.
By the numbers: Fosun Pharma IndustrialDealroom has a profile for this one. Try Dealroom → held 51.77% of Gland Pharma at the end of the June 2026 quarter, making it the largest shareholder. Were it the sole seller of the 4.5% stake, its holding would fall to around 47.3%.
What's the endgame? Gland Pharma, a maker of injectable drugs, posted strong Q1 FY27 results. Net profit rose 47.1% year on year to ₹317 Cr, while revenue climbed 19.6% to ₹1,800.2 Cr and EBITDA margin expanded to 27.2% from 24.4%.
The USFDA also concluded a routine GMP inspection at the company's VSEZ sterile oncology and API facilities with zero Form 483 observations.
The signal: The block deal put the stock under pressure, with shares trading at ₹2,891.20, down 0.57%, by 10:15 EDT. Even so, Gland Pharma has gained 68.48% in 2026 to date. Investors will watch for the promoter's revised holding and any further stake-sale activity.
Read more: sahi.com
Image credit: Generated with Gemini
